Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0ND3F
|
|||
| Drug Name |
LM-030
|
|||
| Indication | Congenital ichthyosiform erythroderma [ICD-11: EC20.02] | Phase 2 | [1] | |
| Company |
LifeMax Laboratories Palo Alto, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Kallikrein-related peptidase (KLK) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.